Kalender

Fetal Alcohol Spectrum Disorders (FASD) are a major public health problem worldwide: alcohol consumption during pregnancy is one of the leading non-genetic and potentially preventable causes of neurodevelopmental disorders (NDDs) and lack of social integration.

In France, for example, it is estimated that nearly 5,000 children are born each year with brain damage due to prenatal alcohol exposure. Rarely screened and then underdiagnosed, these particularly vulnerable children will face disabilities both at school and in everyday life. In adulthood, around 500,000 people are affected to varying degrees. Most of them are unaware of the cause of their troubles and do not receive any specific support, with considerable individual and collective human costs.

However, early detection, diagnosis, and appropriate support starting in early childhood can make a difference and enable each of these people to develop their full potential for a better integration and participation in society.

Awareness of FASD is poor among the general public and even among healthcare professionals, who need an improved training on the subject. Furthermore, fundamental and clinical research is essential to bring about change in FASD and other NDDs: but here again, investment is not in line with the challenges.

In this context, the EUFASD 2026 Conference is an exceptional opportunity at the European level to highlight the issue of FASD and to support objectives aiming at structuring the community of associations, healthcare and support professionals, as well as researchers.

More information

Across three days, the agenda, shaped by our scientific committee of Nature journal editors, will explore key topics shaping the next decade of personalised care:

Omics at the bedside
Translating multi-omics approaches into clinically actionable insights for diagnosis and treatment.

Diversity in data, equity in care
Strengthening global representation in biobanks and risk models to ensure the benefits of precision medicine reach all populations.

Precision health implementation
Tackling infrastructure, governance, regulation and scalability challenges head-on.

Biomarkers and early detection
Discovering and validating predictive molecular signatures across diseases and populations to enable earlier, more precise decision-making.

Precision therapeutics and targeted delivery across the life course
From gene and cell therapies to next-generation vaccines, advances in women’s health, neurodegenerative disease, longevity and more.

Integrating responsible artificial Intelligence in precision health
Embedding machine learning, large language models and digital twins into clinical workflows safely, transparently and with patient trust at the centre.

Secure your place

This meeting is intended to enable researchers in various fields of Paediatric Neurology to meet colleagues in the same field in order to facilitate collaboration, and to foster the building of research networks. The first meeting took place in October 3 – 4, 2008 in Tübingen, Germany in collaboration with the German speaking Paediatric Neurology Society (GNP). This meeting was formerly run as “Wissenschaftliche Statuskonferenz” of the GNP (German-speaking Society of Paediatric Neurology). The general aim of the meeting is to support especially young researchers to meet their colleagues in the field for an exchange in order to facilitate collaboration and to extend or to build up research networks. The programme is structured with parallel sessions for several (currently ten)  10 WORKING GROUPS (approximately 3 hours). Invited plenary lectures of interest to all working groups to be organized by two working groups (4 – 6 lectures, 30 min. per lecture). Feedback from the working groups in plenary sessions.

More information

Enevia Health invites you to AMRS 2026, an international event for multidisciplined researchers, clinicians, medical specialists and families/ carers of Autistic people. This event is specifically dedicated to high-support Autism, a subgroup representing approximately 30% of the Autistic population. Based on a global prevalence of 1% (1 in 100), this corresponds to an estimated 1.35 million individuals in the European Union and over 24 million worldwide. This subgroup of Autistic individuals requires substantial, or very substantial, daily support due to limited functional communication, co-occurring intellectual disability, and significant behavioural or medical complexities. Despite the scale and severity of need, this population remains significantly under-represented in research and greatly underserved in clinical pathways.

More information